Form 4: Viridian Therapeutics, Inc.\DE Executive Reports Stock Trans
Insider Transaction (Form 4)
Radhika Tripuraneni, Chief Medical Officer of Viridian Therapeutics, Inc.\DE, reported multiple transactions in common stock on August 14, 2026.
Summary
- Option exercise/conversion: acquired 40,000 Common Stock at $13.21 ($528,400) on August 14, 2026; holds 40,000 after (Direct).
- Option exercise/conversion: disposed of 40,000 Stock Option (Right to Buy) on August 14, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Radhika Tripuraneni — Officer (Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-14 | Option exercise/conversion | Common Stock | 40,000 | $13 | $528.4K | 40,000 |
| 2026-08-14 | Option exercise/conversion | Stock Option (Right to Buy) | 40,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-14 | Option exercise/conversion (40,000 shares) |
| 2026-08-14 | Option exercise/conversion (40,000 shares) |
Keywords
insider transaction, Form 4, VRDN, Viridian Therapeutics, Inc.\DE, neutral, Radhika Tripuraneni
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.